Trial Profile
A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2020
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Anaemia; Haemorrhage
- Focus Therapeutic Use
- 13 Jul 2020 Status changed from recruiting to completed.
- 19 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 19 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.